“Obesity stocks” is a broader label than most people realize, and that breadth is both the appeal and the danger of the category. The Motley Fool’s “King Kong for Weight Loss” pitch leans on a drug, but the investable universe around obesity stretches from pharmaceutical giants to telehealth platforms to medical devices. Here is what actually sits under that umbrella, and how to separate the different risk profiles hiding inside it.
What Counts as an Obesity Stock
The core of the category is pharmaceutical: the drugmakers developing and selling GLP-1 medicines. That includes the giants, like Novo Nordisk and Eli Lilly, which dominate commercial sales, and the challengers, like Ascendis Pharma with a once-monthly semaglutide and Viking Therapeutics with an oral candidate. These are the names most people mean when they say “obesity stocks,” because the drugs are where the largest revenue opportunity lives.
But the umbrella is wider. Hims & Hers Health is an obesity-adjacent play through its compounded-semaglutide telehealth business, even though it develops no drug of its own. Medical device companies pursuing obesity surgery or related treatments are part of the theme too. The label also stretches to companies working on muscle preservation, on the theory that protecting lean mass during weight loss is the next frontier, which is how a company like Scholar Rock, whose lead drug treats a neuromuscular disease, can get pulled into a weight-loss pitch at all.
Why the Theme Is So Large
The macro case is straightforward. Obesity affects hundreds of millions of people worldwide, the old treatment options were weak, and the new drugs work better than anything that came before. That combination, a huge unmet need plus a genuinely effective product, is the recipe for a massive commercial market. Shortages of the leading drugs are the clearest evidence that demand is running ahead of supply.
The bull case rests on that demand persisting and expanding as oral versions arrive and as insurance coverage slowly improves. Every pill, every monthly injection, and every new indication widens the pool of people who can realistically access the treatment.
The Different Risk Buckets
The most important skill with obesity stocks is sorting them into risk buckets, because the label hides enormous differences. At one end are the diversified pharma giants, whose obesity franchises sit inside much larger businesses, so a single drug’s success or failure does not sink the company. In the middle are revenue-generating biotechs with real growth, like Ascendis Pharma, whose fundamentals you can actually measure. At the other end are pre-revenue clinical-stage companies, like Viking Therapeutics and Veru, where the entire investment case rests on trial data that has not produced a dollar of sales.
Then there is the regulatory bucket. Compounded semaglutide businesses, like the one Hims & Hers operates, depend on branded drugs being officially in shortage. When that shortage resolves, the legal basis for compounding is expected to wind down. That is a different kind of risk entirely, and it does not show up in a headline about “the obesity boom.”
The Role of Urgency in the Pitch
The Fool’s promo wraps all of this in a “buy before October 29” deadline, which is the classic newsletter move of attaching urgency to a theme that is actually multi-year in nature. Our King Kong weight loss teardown could not connect that deadline to any real scheduled event. The obesity market is not going to be won or lost on a single October day. It will play out over the better part of a decade, through trial readouts, regulatory decisions, and format shifts.
How to Invest in the Theme
The disciplined approach is to buy quality on weakness across a long horizon, not to chase a countdown. Diversified giants and revenue-generating challengers can be held for the multi-year story. Pre-revenue biotechs belong in a small, high-risk sleeve, sized so a clinical miss is survivable. For the drug-specific side of the story, see our obesity drug stocks explainer, and for the AI angle that increasingly overlaps with drug development, our AI healthcare stocks piece.
Beyond the Drugs
The obesity theme is bigger than the drugs themselves, and some of the most interesting exposure sits outside the pharma names. Bariatric surgery still has a role, and the device makers that serve it are part of the story. Muscle preservation is emerging as its own sub-theme, because losing lean mass alongside fat is a real clinical concern, and companies working on that problem are getting pulled into the obesity narrative. There are also the distribution and telehealth plays, which monetize the drugs without developing them. Each of these is a different bet on the same underlying trend, and none carries the same risk profile as a drug developer. Investors who want obesity exposure without betting on a single molecule have more options than the pure-play drug names the promo highlights.
Ready to see the research? Click here to access The Motley Fool’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.